Povorcitinib Trial for Hidradenitis Suppurativa
Phase 2
40
about 2.3 years
12–17
23 sites in AL, AZ, CT +14
About this study
Researchers are testing povorcitinib, a medication, in adolescents with moderate to severe hidradenitis suppurativa. The trial will last 832 days and evaluate the drug's safety and effectiveness.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Povorcitinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
kinase inhibitor
Primary: Apparent clearance, Proportion of participants with Treatment-Emergent Adverse Events (TEAEs), Terminal half-life
Secondary: Change from baseline in Children's Dermatology Life Quality Index (CDLQI) score at each visit, Mean change from baseline in abscess count at each visit, Mean change from baseline in draining tunnel count at each visit, Mean change from baseline in inflammatory nodule count at each visit, Mean percentage change from baseline in abscess count at each visit, Mean percentage change from baseline in draining tunnel count at each visit, Mean percentage change from baseline in inflammatory nodule count at each visit, Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)30 among participants with baseline Skin Pain NRS score ≥ 3